Sentences with phrase «year dividend payers»

That's why these 100 - year dividend payers are so unique.

Not exact matches

The blame for the sub-zero performance of last year's top 10 dividend payers fell squarely on a single stock, without which this basket would have rewarded investors with a 7 % gain.

With an aging bull market in the U.S. nearing the end of its seventh year at press time, it's difficult to find safety in cheap stocks; even formerly stodgy dividend payers now trade at dangerously expensive valuations.

Snelson adds that there's still value in many large - cap dividend payers, but be sure to buy the ones that are growing their dividends every year.

To focus on dividend payers that are better positioned to weather a downturn, go with SPDR S&P Dividend (sdy): It's an exchange - traded fund that invests only in large companies healthy enough to have boosted payouts for at least 20 consecutive years, including warhorses like AT&T (t) and Chevrodividend payers that are better positioned to weather a downturn, go with SPDR S&P Dividend (sdy): It's an exchange - traded fund that invests only in large companies healthy enough to have boosted payouts for at least 20 consecutive years, including warhorses like AT&T (t) and ChevroDividend (sdy): It's an exchange - traded fund that invests only in large companies healthy enough to have boosted payouts for at least 20 consecutive years, including warhorses like AT&T (t) and Chevron (cvx).

These risks and uncertainties include: Gilead's ability to achieve its anticipated full year 2018 financial results; Gilead's ability to sustain growth in revenues for its antiviral and other programs; the risk that private and public payers may be reluctant to provide, or continue to provide, coverage or reimbursement for new products, including Vosevi, Yescarta, Epclusa, Harvoni, Genvoya, Odefsey, Descovy, Biktarvy and Vemlidy ®; austerity measures in European countries that may increase the amount of discount required on Gilead's products; an increase in discounts, chargebacks and rebates due to ongoing contracts and future negotiations with commercial and government payers; a larger than anticipated shift in payer mix to more highly discounted payer segments and geographic regions and decreases in treatment duration; availability of funding for state AIDS Drug Assistance Programs (ADAPs); continued fluctuations in ADAP purchases driven by federal and state grant cycles which may not mirror patient demand and may cause fluctuations in Gilead's earnings; market share and price erosion caused by the introduction of generic versions of Viread and Truvada, an uncertain global macroeconomic environment; and potential amendments to the Affordable Care Act or other government action that could have the effect of lowering prices or reducing the number of insured patients; the possibility of unfavorable results from clinical trials involving investigational compounds; Gilead's ability to initiate clinical trials in its currently anticipated timeframes; the levels of inventory held by wholesalers and retailers which may cause fluctuations in Gilead's earnings; Kite's ability to develop and commercialize cell therapies utilizing the zinc finger nuclease technology platform and realize the benefits of the Sangamo partnership; Gilead's ability to submit new drug applications for new product candidates in the timelines currently anticipated; Gilead's ability to receive regulatory approvals in a timely manner or at all, for new and current products, including Biktarvy; Gilead's ability to successfully commercialize its products, including Biktarvy; the risk that physicians and patients may not see advantages of these products over other therapies and may therefore be reluctant to prescribe the products; Gilead's ability to successfully develop its hematology / oncology and inflammation / respiratory programs; safety and efficacy data from clinical studies may not warrant further development of Gilead's product candidates, including GS - 9620 and Yescarta in combination with Pfizer's utomilumab; Gilead's ability to pay dividends or complete its share repurchase program due to changes in its stock price, corporate or other market conditions; fluctuations in the foreign exchange rate of the U.S. dollar that may cause an unfavorable foreign currency exchange impact on Gilead's future revenues and pre-tax earnings; and other risks identified from time to time in Gilead's reports filed with the U.S. Securities and Exchange Commission (the SEC).

We have about $ 650k in cash (which we use to buy & refurb small properties) the aforementioned $ 800k which is a nice mix of tech and F500 dividend payers, and just over $ 1M of retirement accounts - 750 in USA in appl, AMZN, GOOG etc, and $ 260K in UK where I worked for 12 years — BTW the $ 260K was $ 300K pre-Brexit.

Although traditional high dividend payers (think the utilities and telecom sectors) have performed strongly in recent years, they've become quite expensive by most valuation metrics.

Diageo has been a consistent dividend payer since it was created in 1997 by the merger of Guinness and Grand Metropolitan, and it has raised its payout in each of the last six years.

I built a portfolio of about 60 dividend payers all producing between 4 and 7 points for an overall cash flow of about 6 and a half, or a little over 30k a year, without having to sell shares.

Therefore, they're most likely to hold beaten down dividend payers and high yielding REITs, neither of which necessarily present the opportunity for years upon years of dividend growth.

Taking this key metric into account, I ran a screen for dividend payers in the energy and materials sector, trading on a major U.S. exchange with yields better than the 10 - year Treasury and an even more sustainable payout ratio of less than 25 % — lower than the S&P 500 average.

Instead of outperforming by a large margin since 1973, dividend growers returned 12.89 % annually while all dividend payers gained 12.83 % per year and the equally - weighted S&P 500 climbed 12.35 %.

Starting at the top, this robust dividend payer cuts checks equal to 4.5 % of its current market cap in a year.

It might seem a little odd to include an oil and gas MLP in a list of «no doubt» dividend payers given some of the turmoil the industry has faced in recent years.

I built a portfolio of about 60 dividend payers all producing between 4 and 7 points for an overall cash flow of about 6 and a half, or a little over 30k a year, without having to sell shares.

Those with smaller portfolios can begin with a small collection of dividend payers and then slowly add stocks over the course of many years.

Therefore, they're most likely to hold beaten down dividend payers and high yielding REITs, neither of which necessarily present the opportunity for years upon years of dividend growth.

In fact, about 85 % of all rolling three - year periods (and approximately 91 % of all rolling five - year periods) yielded superior returns for dividend payers.

The dividend play may be a bit skewed going into 2013 due to so many special dividends (here are a few special dividend announcements) being paid prior to year - end and a possible exodus from dividend payers -LSB-...]

My last post was devoted to dividend stocks with pep, which highlighted dividend payers that have outperformed over the last year.

Last year only 76 % of dividend payers were profitable whereas this year 87 % of them were in the black.

I find myself with great dividend payers, but have found that my sector weighting is very unconventional.For example 5 % Healthcare & 5 % tech, being 23, I feel that those sectors are going to grow year over year in my lifetime but only hold a small holding so far.

Johnson & Johnson's 2.6 % dividend yield isn't exactly the highest you'll find, but consider that the company is not only a remarkably consistent dividend payer but has increased its dividend for 54 consecutive years.

So if we're sitting here, today, at about 3.5 %, we think that a 3.5 % payer (a really good business) can probably grow its earnings and cash flow, and therefore its dividend, about 4 - 7 % a year, which gets us in the 8 - 10 % total return range.

PSEC has already announced a dividend cut; FSC, a monthly payer, recently suspended dividends for February and will institute a 30 % + dividend cut starting in March ($ 10 a month for me); AI just reported miserable fourth quarter earnings; and PSEC late last year implemented a dividend cut.

1 A «dividend - payer» is a company that has indicated it will pay a dividend within the year.

For those of us who expect stock prices to fall significantly within the next five or ten years, owning a TIPS ladder will allow us to pick up more shares of high quality dividend payers than we can today.

That 30 of the 40 stocks in the S&P 500 energy sector pay dividends helps explain why payers suffered an average decline of 3.08 % last year while non-payers fell 1.27 % on average.

I did some individual stocks about a 1 1/2 years ago that were good dividend payers but the prices skyrocketed out of sight.

Only one new dividend payer arrived in March, and that was HanesBrands (HBI), a company I bought for the first time in Q4 of last year.

Equally weighted slice A, which excludes dividend payers, is not significant at Years 10, 20 and 30.

Among dividend payers, at Year 10 and Year 20, the effect of valuations is larger than the choice of a dividend slice.

If you were assembling a portfolio of dividend payers today, would you ignore the yields of CIBC (5 %) and BMO (4.8 %) simply because they haven't raised their dividends every year since 2005?

Dividend Beginner -[June / 2016]- Subscribe to RSS feed Dividend Beginner is a 22 year old Canadian dividend growth investor striving for financial independence by focusing on high - yielding monthlyDividend Beginner -[June / 2016]- Subscribe to RSS feed Dividend Beginner is a 22 year old Canadian dividend growth investor striving for financial independence by focusing on high - yielding monthlyDividend Beginner is a 22 year old Canadian dividend growth investor striving for financial independence by focusing on high - yielding monthlydividend growth investor striving for financial independence by focusing on high - yielding monthly payers.

It has a rocking chart since its inspection, its a dividend payer stock, its a stock that had increased its dividend over the years, its a company that been around for many years and that had survived the 2008 stock crash and now exceed the value of the before 2008 crash....